of noncardiac chest pain by cognitive‐behavioral therapy and paroxetine. J Psychosom Res 2010; 69:227–235.
95 95 Cannon ROI, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411–1417.
96 96 Prakash C, Clouse RE. Long‐term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999; 44:2373–2379.
97 97 Clouse RE, Lustman PJ, Eckert TC, et al. Low‐dose trazodone for symptomatic patients with esophageal contraction abnormalities. Gastroenterology 1987; 92:1027–1036.
98 98 Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci 2002; 99:8921–8926.
99 99 Rao SSC, Mudipalli RS, Mujica V, et al. An open‐label trial of theophylline for functional chest pain. Dig Dis Sci 2002; 47:2763–2768.
100 100 Rao SSC, Mudipalli RS, Remes‐Troche JM, et al. Theophylline improves esophageal chest pain? A randomized, placebo‐controlled study. Am J Gastroenterol 2007; 102:930–938.
101 101 Hu Y, Yu X, Yu S. QX‐314 inhibits acid‐induced activation of esophageal nociceptive C fiber neurons. Neurogastroenterol Motil 2019:1–7.
102 102 Yeh JZ. Sodium inactivation mechanism modulates QX‐314 block of sodium channels in squid axons. Biophys J 1978; 24:569–574.
103 103 Connors BW, Prince DA. Effects of local anesthetic QX‐314 on the membrane properties of hippocampal pyramidal neurons. J Pharmacol Exp Ther 1982; 220:476–481.
104 104 Binshtok AM, Bean BP, Woolf CJ. Inhibition of nociceptors by TRPV1–mediated entry of impermeant sodium channel blockers. Nature 2007; 449:607–610.
105 105 Talbot S, Abdulnour R‐EE, Burkett PR, et al. Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation. Neuron 2015; 87:341–354.
106 106 Keefer L, Palsson OS, Pandolfino JE. Best practice update: incorporating psychogastroenterology into management of digestive disorders. Gastroenterology 2018; 154:1249–1257.
107 107 Klimes I, Mayou RA, Pearce MJ, et al. Psychological treatment for atypical non‐cardiac chest pain: a controlled evaluation. Psychol Med 1990; 20:605–611.
108 108 Mayou R, Bryant B, Sanders D, et al. A controlled trial of cognitive behavioural therapy for non‐cardiac chest pain. Psychol Med 1997; 27:S0033291797005254.
109 109 Potts SG. Group psychological treatment for chest pain with normal coronary arteries. QJM 1999; 92:81–86.
110 110 van Peski‐Oosterbaan AS, Spinhoven P, van Rood Y, et al. Cognitive‐behavioral therapy for noncardiac chest pain: a randomized trial. Am J Med 1999; 106:424–429.
111 111 Jonsbu E, Dammen T, Morken G, et al. Short‐term cognitive behavioral therapy for non‐cardiac chest pain and benign palpitations: A randomized controlled trial. J Psychosom Res 2011; 70:117–123.
112 112 van Beek MHCT, Oude Voshaar RC, Beek AM, et al. A brief cognitive‐behaviroal intervention for treating depression and panic disorder in patients with noncardiac chest pain: a 24–week randomized controlled trialz. Depress Anxiety 2013; 30:670–678.
113 113 Shapiro M, Shanani R, Taback H, et al. Functional chest pain responds to biofeedback treatment but functional heartburn does not. Eur J Gastroenterol Hepatol 2012; 24:708–714.
114 114 Jones H. Treatment of non‐cardiac chest pain: a controlled trial of hypnotherapy. Gut 2006; 55:1403–1408.
115 115 Johrei OM. Divine light of salvation. 1st ed. Kyoto, Japan: Society of Johrei; 1984.
116 116 Gasiorowska A, Navarro‐Rodriguez T, Dickman R, et al. Clinical trial: The effect of Johrei on symptoms of patients with functional chest pain. Aliment Pharmacol Ther 2009; 29:126–134.
117 117 Kisely SR, Campbell LA, Yelland MJ, et al. Psychological interventions for symptomatic management of non‐specific chest pain in patients with normal coronary anatomy. Cochrane Database Syst Rev June 2015.
118 118 Walmart, $4 prescription list, https://www.walmart.com/cp/$4–prescriptions/1078664.
119 119 GoodRx, Imipramine, https://www.goodrx.com/imipramine‐hydrochloride.
120 120 Milavetz G, Vaughan LM, Weinberger MM, et al. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. J Pediatr 1986; 109:351–354.
121 121 Skinner MH. Adverse reactions and interactions with theophylline. Drug Saf 1990; 5:275–285.
122 122 Sadowski DC, Ackah F, Jiang B, et al. Achalasia: incidence, prevalence and survival. A population‐based study. Neurogastroenterol Motil 2010; 22:e256–e261.
123 123 Roman S, Huot L, Zerbib F, et al. High‐resolution manometry improves the diagnosis of esophageal motility disorders in patients with dysphagia: A randomized multicenter study. Am J Gastroenterol 2016; 111:372–380.
124 124 Rohof WOA, Bredenoord AJ. Chicago classification of esophageal motility disorders: Lessons Learned. Curr Gastroenterol Rep 2017; 19:1–6.
125 125 Goldblum J, Rice T, Richter J. Histopathologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology 1996; 111:648–654.
126 126 Clark SB, Rice TW, Tubbs RR, et al. The nature of the myenteric infiltrate in achalasia. Am J Surg Pathol 2000; 24:1153–1158.
127 127 Villanacci V, Annese V, Cuttitta A, et al. An immunohistochemical study of the myenteric plexus in idiopathic achalasia. J Clin Gastroenterol 2010; 44:407–410.
128 128 Kilic A, Owens SR, Pennathur A, et al. An increased proportion of inflammatory cells express tumor necrosis factor alpha in idiopathic achalasia of the esophagus. Dis Esophagus 2009; 22:382–385.
129 129 Storch WB, Eckardt VF, Junginger T. Complement components and terminal complement complex in oesophageal smooth muscle of patients with achalasia. Cell Mol Biol (Noisy‐le‐grand) 2002; 48:247–252.
130 130 Verne GN, Hahn AB, Pineau BC, et al. Association of HLA‐DR and ‐DQ alleles with idiopathic achalasia. Gastroenterology 1999; 117:26–31.
131 131 Verne GN, Sallustio JE, Eaker EY. Anti‐myenteric neuronal antibodies in patients with achalasia. A prospective study. Dig Dis Sci 1997; 42:307–313.
132 132 Niwamoto H, Okamoto E, Fujimoto J, et al. Are human herpes viruses or measles virus associated with esophageal achalasia? Dig Dis Sci 1995; 40:859–864.
133 133 Birgisson S, Galinski MS, Goldblum JR, et al. Achalasia is not associated with measles or known herpes and human papilloma viruses. Dig Dis Sci 1997; 42:300–306.
134 134 Facco M, Brun P, Baesso I, et al. T cells in the myenteric plexus of achalasia patients show a skewed TCR repertoire and react to HSV‐1 Antigens. Am J Gastroenterol 2008; 103:1598–1609.
135 135 Robertson CS, Martin BAB, Atkinson M. Varicella‐zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut 1993; 34:299–302.
136 136 Castagliuolo I. Esophageal achalasia: Is the herpes simplex virus really innocent? J Gastrointest Surg 2004; 8:24–30.
137 137 Jeon HH, Kim J‐H, Youn YH, et al. Clinical characteristics of patients with untreated achalasia. J Neurogastroenterol Motil 2017; 23:378–384.
138 138 Jung DH, Park H. Is Gastroesophageal reflux disease and achalasia coincident or not? J Neurogastroenterol Motil 2017; 23:5–8.
139 139 Massey BT, Hogan WJ, Dodds WJ, et al. Alteration of the upper esophageal sphincter belch reflex in patients with achalasia. Gastroenterology 1992; 103:1574–1579.
140 140 Howard PJ, Maher L, Pryde A, et al. Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in